{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:05:23Z","timestamp":1790255123275,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008672","name":"Wilhelm Sander Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner Fresenius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omton.2026.201277","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:41:43Z","timestamp":1781714503000},"page":"201277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Augmenting CAR T cell functionality and metabolism through CD39 downtuning"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7512-572X","authenticated-orcid":false,"given":"Dennis Christoph","family":"Harrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Barden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bence","family":"Gergely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1rp\u00e1d","family":"Sz\u00f6\u0151r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Vereb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hinrich","family":"Abken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omton.2026.201277_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric Antigen Receptor Therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omton.2026.201277_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1159\/000525052","article-title":"Treatment with Living Drugs: Pharmaceutical Aspects of CAR T Cells","volume":"107","author":"Holzinger","year":"2022","journal-title":"Pharmacology"},{"key":"10.1016\/j.omton.2026.201277_bib3","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00262-022-03163-y","article-title":"Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials","volume":"71","author":"Ormh\u00f8j","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.omton.2026.201277_bib4","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3390\/cancers12092567","article-title":"The Landscape of CAR-T Cell Clinical Trials against Solid Tumors\u2014A Comprehensive Overview","volume":"12","author":"Schaft","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.omton.2026.201277_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.795164","article-title":"Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?","volume":"13","author":"Safarzadeh Kozani","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201277_bib6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omton.2026.201277_bib7","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion","volume":"19","author":"Blank","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omton.2026.201277_bib8","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41586-019-1805-z","article-title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","volume":"576","author":"Lynn","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.omton.2026.201277_bib9","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","article-title":"T Cell Dysfunction in Cancer","volume":"33","author":"Thommen","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201277_bib10","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201277_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molimm.2021.06.007","article-title":"Targeted knockdown of Tim3 by short hairpin RNAs improves the function of anti-mesothelin CAR T cells","volume":"139","author":"Jafarzadeh","year":"2021","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.omton.2026.201277_bib12","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1007\/s11684-017-0543-6","article-title":"CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells","volume":"11","author":"Zhang","year":"2017","journal-title":"Front. Med."},{"key":"10.1016\/j.omton.2026.201277_bib13","article-title":"Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function","volume":"32","author":"Veliz","year":"2024","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.omton.2026.201277_bib14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ymthe.2021.10.004","article-title":"PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells","volume":"30","author":"Lee","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omton.2026.201277_bib15","doi-asserted-by":"crossref","first-page":"8068","DOI":"10.3390\/ijms22158068","article-title":"CD39 Regulation and Functions in T Cells","volume":"22","author":"Timperi","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.omton.2026.201277_bib16","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.immuni.2022.12.001","article-title":"The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer","volume":"56","author":"Chow","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201277_bib17","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.celrep.2016.01.002","article-title":"Expression of CD39 on Activated T Cells Impairs their Survival in Older Individuals","volume":"14","author":"Fang","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201277_bib18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8+ T Cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.omton.2026.201277_bib19","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41590-022-01379-9","article-title":"Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity","volume":"24","author":"Vignali","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.omton.2026.201277_bib20","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking Antibodies Targeting the CD39\/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.omton.2026.201277_bib21","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1158\/2159-8290.CD-19-0541","article-title":"Targeting CD39 in Cancer Reveals an Extracellular ATP- and Inflammasome-Driven Tumor Immunity","volume":"9","author":"Li","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.omton.2026.201277_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201277_bib23","doi-asserted-by":"crossref","first-page":"6249","DOI":"10.7150\/thno.97590","article-title":"Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies","volume":"14","author":"Zhang","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.omton.2026.201277_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1185618","article-title":"IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities","volume":"14","author":"Harrer","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omton.2026.201277_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.omton.2026.201277_bib26","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.3390\/cells11233839","article-title":"CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop","volume":"11","author":"Harrer","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.omton.2026.201277_bib27","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.immuni.2009.05.014","article-title":"Transcriptional Repressor Blimp-1 Promotes CD8+ T Cell Terminal Differentiation and Represses the Acquisition of Central Memory T Cell Properties","volume":"31","author":"Rutishauser","year":"2009","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201277_bib28","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.immuni.2017.11.021","article-title":"Transcription Factor IRF4 Promotes CD8+ T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection","volume":"47","author":"Man","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201277_bib29","doi-asserted-by":"crossref","first-page":"12410","DOI":"10.1073\/pnas.1905675116","article-title":"TOX and TOX2 transcription factors cooperate with NR4A transcription factors to impose CD8+ T cell exhaustion","volume":"116","author":"Seo","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omton.2026.201277_bib30","doi-asserted-by":"crossref","first-page":"6081","DOI":"10.1016\/j.cell.2021.11.016","article-title":"An NK-like CAR T cell transition in CAR T cell dysfunction","volume":"184","author":"Good","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omton.2026.201277_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.omton.2026.201277_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111339","article-title":"ShRNA-mediated silencing of PD-1 augments the efficacy of chimeric antigen receptor T cells on subcutaneous prostate and leukemia xenograft","volume":"137","author":"Zhou","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.omton.2026.201277_bib33","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1038\/s41467-019-11893-4","article-title":"Engineered triple inhibitory receptor resistance improves anti-tumor CAR-T cell performance via CD56","volume":"10","author":"Zou","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omton.2026.201277_bib34","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.3390\/ijms23063207","article-title":"Simultaneous Genetic Ablation of PD-1, LAG-3, and TIM-3 in CD8 T Cells Delays Tumor Growth and Improves Survival Outcome","volume":"23","author":"Ciraolo","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.omton.2026.201277_bib35","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.immuni.2023.09.001","article-title":"Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells","volume":"56","author":"Agarwal","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.omton.2026.201277_bib36","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1136\/gutjnl-2022-328042","article-title":"Revealing and harnessing CD39 for the treatment of colorectal cancer and liver metastases by engineered T cells","volume":"72","author":"Potenza","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.omton.2026.201277_bib37","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","article-title":"Impact of the selective A2AR and A2BR dual antagonist AB928\/etrumadenant on CAR T cell function","volume":"127","author":"Seifert","year":"2022","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.omton.2026.201277_bib38","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.ymthe.2019.06.007","article-title":"Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30\u2212 Tumors","volume":"27","author":"Hombach","year":"2019","journal-title":"Mol. Ther."}],"container-title":["Molecular Therapy Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950329926001530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:36:59Z","timestamp":1790253419000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950329926001530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2950329926001530"],"URL":"https:\/\/doi.org\/10.1016\/j.omton.2026.201277","relation":{},"ISSN":["2950-3299"],"issn-type":[{"value":"2950-3299","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Augmenting CAR T cell functionality and metabolism through CD39 downtuning","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omton.2026.201277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201277"}}